

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/002476-2021>

Award

## **Thrombotic Thrombocytopenic Purpura (TTP)**

NHS England - Specialised Commissioning

F15: Voluntary ex ante transparency notice

Notice identifier: 2021/S 000-002476

Procurement identifier (OCID): ocds-h6vhtk-029113

Published 8 February 2021, 1:35pm

### **Section I: Contracting authority/entity**

#### **I.1) Name and addresses**

NHS England - Specialised Commissioning

80 London Road,

London

SE1 6LH

#### **Email**

[Lisa.Innes1@nhs.net](mailto:Lisa.Innes1@nhs.net)

#### **Country**

United Kingdom

#### **NUTS code**

UK - UNITED KINGDOM

**Internet address(es)**

Main address

<https://www.ardengemcsu.nhs.uk/>

**I.4) Type of the contracting authority**

Body governed by public law

**I.5) Main activity**

Health

---

## **Section II: Object**

### **II.1) Scope of the procurement**

#### **II.1.1) Title**

Thrombotic Thrombocytopenic Purpura (TTP)

Reference number

NHS England Spec. Commissioning

#### **II.1.2) Main CPV code**

- 85000000 - Health and social work services

#### **II.1.3) Type of contract**

Services

#### **II.1.4) Short description**

Thrombotic Thrombocytopenic Purpura (TTP) is a serious blood disorder that results in blood clots forming in small blood vessels throughout the body. It affects the kidneys, heart and brain. If a patient is treated outside a specialist centre, mortality is 50%; in a specialist centre, it is 20%. There is also an appreciable acute morbidity, particularly in neurological disorders.

The condition can be difficult to diagnose because initial presentation can be non-specific. Rapid treatment is essential for optimal outcomes and includes plasma exchange and a range of drugs. This disease primarily affects adults. Children are treated in paediatric haematology centres and are outside the scope of this process.

#### **II.1.6) Information about lots**

This contract is divided into lots: Yes

#### **II.1.7) Total value of the procurement (excluding VAT)**

Value excluding VAT: £25,600,000

### **II.2) Description**

**II.2.1) Title**

Thrombotic Thrombocytopenic Purpura (TTP) – London and parts of the South East (Kent, Surrey & Sussex)

Lot No

1

**II.2.2) Additional CPV code(s)**

- 85000000 - Health and social work services
- 85100000 - Health services

**II.2.3) Place of performance**

NUTS codes

- UKJ - SOUTH EAST (ENGLAND)
- UKI - LONDON

Main site or place of performance

London and parts of the South East (Kent, Surrey and Sussex).

**II.2.4) Description of the procurement**

TTP is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient's blood is filtered and then put back into their body). The prevalence is 330 patients in England, with an acute incidence of 150 patients.

There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are two centres in England where there are recognised services.

The Commissioners are planning to initially enter into contract with two providers for a term of four years to provide cover for patients in (a) the North West and (b) London and parts of the South East. The reasons for this decision are:

- The providers are the only two fully capable providers with recognised established services to meet the specification and will offer access to services, whilst new providers are identified through a competitive process to ensure access to services across England;
- The two providers have full capacity and the necessary skills to deliver the service and have been assessed as meeting the service requirements and thus are eligible to be commissioned by NHS England and Improvement.

Commissioners have undertaken a negotiated procedure without prior publication and have undertaken a due diligence assessment of the two Providers. They were required to complete a self-assessment questionnaire to ensure quality of service provision; which was approved as part of the strategic approach to commissioning these services and is in line with Commissioners internal governance mechanisms/processes to award these services.

While the Commissioners are intending to award a contract for services across London and parts of the South East (Kent, Surrey & Sussex) based on the negotiated procedure without publication, they wish to seek further expression of interest, which is due to be published in February 2021, to secure provision for up to a further 7 Lots across England which includes South West, West Midlands, East Midlands, East of England, North East, Yorkshire and Humber and parts of the South East (Thames Valley, Hampshire and the Isle of Wight)\*.

Providers who are interested in these future opportunities will be required to register and respond separately to any future Notice as applicable, published in line with the regulations following conclusion of this notice.

\*Note, in securing the provision for parts of the South East, the Commissioners require the successful provider to work with the already established London provider. This will support shared care and improve local patient access to the service whilst ensuring availability of clinical expertise as appropriate.

## **II.2.11) Information about options**

Options: No

## **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

## **II.2) Description**

### **II.2.1) Title**

Thrombotic Thrombocytopenic Purpura (TTP) – North West

Lot No

2

## **II.2.2) Additional CPV code(s)**

- 85000000 - Health and social work services
- 85100000 - Health services

## **II.2.3) Place of performance**

NUTS codes

- UKD - NORTH WEST (ENGLAND)

Main site or place of performance

North West

## **II.2.4) Description of the procurement**

TTP is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient's blood is filtered and then put back into their body). The prevalence is 330 patients in England, with an acute incidence of 150 patients.

There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are two centres in England where there are recognised services.

The Commissioners are planning to initially enter into contract with two providers for a term of four years to provide cover for patients in (a) the North West and (b) London and parts of the South East across England. The reasons for this decision are:

- The providers are the only two fully capable providers with recognised established services to meet the specification and will offer access to services, whilst new providers are identified through a competitive process to ensure access to services across England;

- The two providers have full capacity and the necessary skills to deliver the service and have been assessed as meeting the service requirements and thus are eligible to be commissioned by NHS England and Improvement.

Commissioners have undertaken a negotiated procedure without prior publication and have undertaken a due diligence assessment of the two Providers, who were required to complete a self-assessment questionnaire to ensure quality of service provision; which was then approved as part of the strategic approach to commissioning these services and is in line with Commissioners internal governance mechanisms/processes to award these services.

While the Commissioners are intending to award a contract for services across London and parts of the South East (Kent, Surrey & Sussex) based on the negotiated procedure without publication, they wish to seek further expression of interest, which is due to be published in February 2021, to secure provision for up to a further 7 Lots across England, which includes South West, West Midlands, East Midlands, East of England, North East, Yorkshire and Humber and parts of the South East (Thames Valley, Hampshire and the Isle of Wight)\*.

Providers who are interested in these future opportunities will be required to register and respond separately to any future Notice as applicable, published in line with the regulations following conclusion of this notice

\*Note, in securing the provision for parts of the South East, the Commissioners require the successful provider to work with the already established London provider. This will support shared care and improve local patient access to the service whilst ensuring availability of clinical expertise as appropriate.

### **II.2.11) Information about options**

Options: No

### **II.2.13) Information about European Union Funds**

The procurement is related to a project and/or programme financed by European Union funds: No

---

## **Section IV. Procedure**

### **IV.1) Description**

#### **IV.1.1) Type of procedure**

Negotiated without a prior call for competition

- The works, supplies or services can be provided only by a particular economic operator for the following reason:
  - absence of competition for technical reasons

#### Explanation:

The current pathway of care is disjointed and there was a need to review delivery in order to improve outcomes for patients. The current pattern shows patients receiving varying level of care with some patients treated in expert centres whereas others without access to expert advice.

Due to the disjointed nature of the current TPP provision and the high mortality rate, the Prescribed Specialised Services Advisory Group (PSSAG) has requested that NHS England assume the commissioning responsibility for this disease, with the aim of establishing appropriate number of expert centres and clear and defined pathways to improve patient outcomes.

To address the issues identified in the current provision, a new service delivery model and service specification has been developed, where the principle elements are:

- Early diagnosis and commencement on apheresis.
- Access to apheresis must be 24/7
- Patients require acute inpatient admission, which include ITU.
- This disease is lifelong, and the expert centres must provide life monitoring and early intervention if the patient relapses.
- A requirement for a treating and educative/outreach role to raise awareness of the disease, as the disease can present with non-specific symptoms in the early stages.

The Commissioners recognise the importance of striking the right balance between geographical access, population and the need to maintain expertise and are working towards implementing the new delivery model.

#### **IV.1.8) Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: No



---

## **Section V. Award of contract/concession**

### **Contract No**

1

### **Lot No**

1

### **Title**

Thrombotic Thrombocytopenic Purpura (TTP) – London and parts of the South East (Kent, Surrey & Sussex).

A contract/lot is awarded: Yes

### **V.2) Award of contract/concession**

#### **V.2.1) Date of conclusion of the contract**

18 January 2021

#### **V.2.2) Information about tenders**

The contract has been awarded to a group of economic operators: No

#### **V.2.3) Name and address of the contractor/concessionaire**

University College London Hospitals NHS Foundation Trust

250 Euston Road

London

NW1 2PG

Country

United Kingdom

NUTS code

- UKI - LONDON

The contractor/concessionaire is an SME

No

#### **V.2.4) Information on value of contract/lot/concession (excluding VAT)**

Total value of the contract/lot/concession: £20,700,000

---

### **Section V. Award of contract/concession**

#### **Contract No**

2

#### **Lot No**

2

#### **Title**

Thrombotic Thrombocytopenic Purpura (TTP) – North West

A contract/lot is awarded: Yes

#### **V.2) Award of contract/concession**

##### **V.2.1) Date of conclusion of the contract**

21 December 2020

##### **V.2.2) Information about tenders**

The contract has been awarded to a group of economic operators: No

##### **V.2.3) Name and address of the contractor/concessionaire**

Liverpool University Hospitals NHS Foundation Trust

Prescot Street

Liverpool

L7 8XP

Country

United Kingdom

NUTS code

- UKD - NORTH WEST (ENGLAND)

The contractor/concessionaire is an SME

No

#### **V.2.4) Information on value of contract/lot/concession (excluding VAT)**

Total value of the contract/lot/concession: £4,900,000

---

## **Section VI. Complementary information**

### **VI.3) Additional information**

- This is a voluntary ex ante transparency notice for the award of two contracts for Thrombotic Thrombocytopenic Purpura (TTP) – London and parts of the South (Kent, Surrey & Sussex).

- This notice has been published to notify the market of the Commissioners intention to enter into a contract with the providers named within. There will be no further standstill period and Commissioners will enter into contracts following conclusion of this notice.

- Any legal action must be brought promptly in the High Court and within the time limits as defined in the Public Contracts Regulations 2015.

- Contract values are indicative based on a projected baseline for 2021-2022 with forecasted growth over the term of the contract.

### **VI.4) Procedures for review**

#### **VI.4.1) Review body**

Arden & GEM Commissioning Support Unit

Derby

Country

United Kingdom

### **VI.4.3) Review procedure**

Precise information on deadline(s) for review procedures

Precise information on deadline(s) for review procedures:

- This is a voluntary ex ante transparency notice for the award of two contracts for Thrombotic Thrombocytopenic Purpura (TTP) - London and parts of the South East (Kent, Surrey & Sussex).
- This notice has been published to notify the market of the Commissioners intention to enter into a contract with the providers named within. There will be no further standstill period and Commissioners will enter into contracts following conclusion of this notice.
- Any legal action must be brought promptly in the High Court and within the time limits as defined in the Public Contracts Regulations 2015

### **VI.4.4) Service from which information about the review procedure may be obtained**

Arden & GEM Commissioning Support Unit

Derby

Country

United Kingdom